Interferons in Sjögren's syndrome: Genes, mechanisms, and effects

Frontiers in Immunology

Volumn 4, Issue SEP, 2013, Pages

  Li, He ^a,b   Ice, John A ^a   Lessard, Christopher J ^a,b   Sivils, Kathy L ^a,b  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Biomarker; Gene expression profiling; Genetic association; Interferon signature; Mechanisms; Microarrays; Sj gren's syndrome; Type I interferon

Indexed keywords

AUTOANTIBODY; B CELL ACTIVATING FACTOR; CXCL13 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERFERON; INTERLEUKIN 8; TRIPARTITE MOTIF CONTAINING PROTEIN 21; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

APOPTOSIS; DNA MICROARRAY; GENE; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; HUMAN; IMMUNE DYSREGULATION; IMMUNE RESPONSE; LYMPHOCYTIC INFILTRATION; NONHUMAN; PATHOPHYSIOLOGY; PLASMACYTOID DENDRITIC CELL; SHORT SURVEY; SIGNAL TRANSDUCTION; SJOEGREN SYNDROME;

EID: 84886057701     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2013.00290     Document Type: Short Survey

References (83)

1. Alamanos Y, Tsifetaki N, Voulgari PV, Venetsanopoulou AI, Siozos C, Drosos AA. Epidemiology of primary Sjogren's syndrome in north-west Greece, 1982-2003. Rheumatology (Oxford) (2006) 45(2):187-91. doi:10.1093/rheumatology/kei107.
2. Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum (2008) 58(1):15-25. doi:10.1002/art.23177.
3. Jonsson R, Vogelsang P, Volchenkov R, Espinosa A, Wahren-Herlenius M, Appel S. The complexity of Sjogren's syndrome: novel aspects on pathogenesis. Immunol Lett (2011) 141(1):1-9. doi:10.1016/j.imlet.2011.06.007.
4. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis (2002) 61(6):554-8. doi:10.1136/ard.61.6.554.
5. Hernandez-Molina G, Leal-Alegre G, Michel-Peregrina M. The meaning of anti-Ro and anti-La antibodies in primary Sjogren's syndrome. Autoimmun Rev (2011) 10(3):123-5. doi:10.1016/j.autrev.2010.09.001.
6. Båve U, Nordmark G, Lovgren T, Ronnelid J, Cajander S, Eloranta ML, et al. Activation of the type I interferon system in primary Sjogren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum (2005) 52(4):1185-95. doi:10.1002/art.20998.
7. Hjelmervik TO, Petersen K, Jonassen I, Jonsson R, Bolstad AI. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjogren's syndrome patients from healthy control subjects. Arthritis Rheum (2005) 52(5):1534-44. doi:10.1002/art.21006.
8. Gottenberg JE, Cagnard N, Lucchesi C, Letourneur F, Mistou S, Lazure T, et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren's syndrome. Proc Natl Acad Sci USA (2006) 103(8):2770-5. doi:10.1073/pnas.0510837103.
9. Emamian ES, Leon JM, Lessard CJ, Grandits M, Baechler EC, Gaffney PM, et al. Peripheral blood gene expression profiling in Sjogren's syndrome. Genes Immun (2009) 10(4):285-96. doi:10.1038/gene.2009.20.
10. Pérez P, Anaya JM, Aguilera S, Urzua U, Munroe D, Molina C, et al. Gene expression and chromosomal location for susceptibility to Sjogren's syndrome. J Autoimmun (2009) 33(2):99-108. doi:10.1016/j.jaut.2009.05.001.
11. Gonzalez-Navajas JM, Lee J, David M, Raz E. Immunomodulatory functions of type I interferons. Nat Rev Immunol (2012) 12(2):125-35. doi:10.1038/nri3133.
12. Igoe A, Scofield RH. Autoimmunity and infection in Sjogren's syndrome. Curr Opin Rheumatol (2013) 25(4):480-7. doi:10.1097/BOR.0b013e32836200d2.
13. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA (2003) 100(5):2610-5. doi:10.1073/pnas.0337679100.
14. Higgs BW, Liu Z, White B, Zhu W, White WI, Morehouse C, et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis (2011) 70(11):2029-36. doi:10.1136/ard.2011.150326.
15. O'Neill LA, Golenbock D, Bowie AG. The history of Toll-like receptors-redefining innate immunity. Nat Rev Immunol (2013) 13(6):453-60. doi:10.1038/nri3446.
16. Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol (2005) 23:275-306. doi:10.1146/annurev.immunol.23.021704.115633.
17. Savitsky D, Tamura T, Yanai H, Taniguchi T. Regulation of immunity and oncogenesis by the IRF transcription factor family. Cancer Immunol Immunother (2010) 59(4):489-510. doi:10.1007/s00262-009-0804-6.
18. Abu-Helu RF, Dimitriou ID, Kapsogeorgou EK, Moutsopoulos HM, Manoussakis MN. Induction of salivary gland epithelial cell injury in Sjogren's syndrome: in vitro assessment of T cell-derived cytokines and Fas protein expression. J Autoimmun (2001) 17(2):141-53. doi:10.1006/jaut.2001.0524.
19. Nordmark G, Alm GV, Ronnblom L. Mechanisms of disease: primary Sjogren's syndrome and the type I interferon system. Nat Clin Pract Rheumatol (2006) 2(5):262-9. doi:10.1038/ncprheum0173.
20. Ohyama Y, Nakamura S, Matsuzaki G, Shinohara M, Hiroki A, Fujimura T, et al. Cytokine messenger RNA expression in the labial salivary glands of patients with Sjogren's syndrome. Arthritis Rheum (1996) 39(8):1376-84. doi:10.1002/art.1780390816.
21. Mitsias DI, Tzioufas AG, Veiopoulou C, Zintzaras E, Tassios IK, Kogopoulou O, et al. The Th1/Th2 cytokine balance changes with the progress of the immunopathological lesion of Sjogren's syndrome. Clin Exp Immunol (2002) 128(3):562-8. doi:10.1046/j.1365-2249.2002.01869.x.
22. Wakamatsu E, Matsumoto I, Yasukochi T, Naito Y, Goto D, Mamura M, et al. Overexpression of phosphorylated STAT-1alpha in the labial salivary glands of patients with Sjogren's syndrome. Arthritis Rheum (2006) 54(11):3476-84. doi:10.1002/art.22176.
23. Giron-Gonzalez JA, Baturone R, Soto MJ, Marquez M, Macias I, Montes de Oca M, et al. Implications of immunomodulatory interleukins for the hyperimmunoglobulinemia of Sjogren's syndrome. Cell Immunol (2009) 259(1):56-60. doi:10.1016/j.cellimm.2009.05.013.
24. Szodoray P, Papp G, Horvath IF, Barath S, Sipka S, Nakken B, et al. Cells with regulatory function of the innate and adaptive immune system in primary Sjogren's syndrome. Clin Exp Immunol (2009) 157(3):343-9. doi:10.1111/j.1365-2249.2009.03966.x.
25. Hu S, Wang J, Meijer J, Ieong S, Xie Y, Yu T, et al. Salivary proteomic and genomic biomarkers for primary Sjogren's syndrome. Arthritis Rheum (2007) 56(11):3588-600. doi:10.1002/art.22954.
26. Wildenberg ME, van Helden-Meeuwsen CG, van de Merwe JP, Drexhage HA, Versnel MA. Systemic increase in type I interferon activity in Sjogren's syndrome: a putative role for plasmacytoid dendritic cells. Eur J Immunol (2008) 38(7):2024-33. doi:10.1002/eji.200738008.
27. Zheng L, Zhang Z, Yu C, Tu L, Zhong L, Yang C. Association between IFN-alpha and primary Sjogren's syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2009) 107(1):e12-8. doi:10.1016/j.tripleo.2008.09.015.
28. Theofilopoulos AN, Baccala R, Beutler B, Kono DH. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol (2005) 23:307-36. doi:10.1146/annurev.immunol.23.021704.115843.
29. Farkas L, Beiske K, Lund-Johansen F, Brandtzaeg P, Jahnsen FL. Plasmacytoid dendritic cells (natural interferon-alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol (2001) 159(1):237-43. doi:10.1016/S0002-9440(10)61689-6.
30. Van Krinks CH, Matyszak MK, Gaston JS. Characterization of plasmacytoid dendritic cells in inflammatory arthritis synovial fluid. Rheumatology (Oxford) (2004) 43(4):453-60. doi:10.1093/rheumatology/keh115.
31. Nordmark G, Eloranta ML, Ronnblom L. Primary Sjogren's syndrome and the type I interferon system. Curr Pharm Biotechnol (2012) 13(10):2054-62. doi:10.2174/138920112802273290.
32. Fitzgerald-Bocarsly P, Dai J, Singh S. Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history. Cytokine Growth Factor Rev (2008) 19(1):3-19. doi:10.1016/j.cytogfr.2007.10.006.
33. Poole BD, Scofield RH, Harley JB, James JA. Epstein-Barr virus and molecular mimicry in systemic lupus erythematosus. Autoimmunity (2006) 39(1):63-70. doi:10.1080/08916930500484849.
34. Salomonsson S, Wahren-Herlenius M. Local production of Ro/SSA and La/SSB autoantibodies in the target organ coincides with high levels of circulating antibodies in sera of patients with Sjogren's syndrome. Scand J Rheumatol (2003) 32(2):79-82. doi:10.1080/03009740310000076.
35. Wahren-Herlenius M, Salomonsson S. Detection of antigen specific B-cells in tissues. Methods Mol Med (2007) 136:19-24. doi:10.1007/978-1-59745-402-5_2.
36. Lövgren T, Eloranta ML, Kastner B, Wahren-Herlenius M, Alm GV, Ronnblom L. Induction of interferon-alpha by immune complexes or liposomes containing systemic lupus erythematosus autoantigen-and Sjogren's syndrome autoantigen-associated RNA. Arthritis Rheum (2006) 54(6):1917-27. doi:10.1002/art.21893.
37. Higgs R, Ni Gabhann J, Ben Larbi N, Breen EP, Fitzgerald KA, Jefferies CA. The E3 ubiquitin ligase Ro52 negatively regulates IFN-beta production post-pathogen recognition by polyubiquitin-mediated degradation of IRF3. J Immunol (2008) 181(3):1780-6.
38. Higgs R, Lazzari E, Wynne C, Ni Gabhann J, Espinosa A, Wahren-Herlenius M, et al. Self protection from anti-viral responses-Ro52 promotes degradation of the transcription factor IRF7 downstream of the viral Toll-Like receptors. PLoS ONE (2010) 5(7):e11776. doi:10.1371/journal.pone.0011776.
39. Espinosa A, Hennig J, Ambrosi A, Anandapadmanaban M, Abelius MS, Sheng Y, et al. Anti-Ro52 autoantibodies from patients with Sjogren's syndrome inhibit the Ro52 E3 ligase activity by blocking the E3/E2 interface. J Biol Chem (2011) 286(42):36478-91. doi:10.1074/jbc. M111.241786.
40. Espinosa A, Dardalhon V, Brauner S, Ambrosi A, Higgs R, Quintana FJ, et al. Loss of the lupus autoantigen Ro52/Trim21 induces tissue inflammation and systemic autoimmunity by disregulating the IL-23-Th17 pathway. J Exp Med (2009) 206(8):1661-71. doi:10.1084/jem.20090585.
41. Niewold TB, Rivera TL, Buyon JP, Crow MK. Serum type I interferon activity is dependent on maternal diagnosis in anti-SSA/Ro-positive mothers of children with neonatal lupus. Arthritis Rheum (2008) 58(2):541-6. doi:10.1002/art.23191.
42. Scofield RH, Kurien BT, Reichlin M. Immunologically restricted and inhibitory anti-Ro/SSA in monozygotic twins. Lupus (1997) 6(4):395-8. doi:10.1177/096120339700600409.
43. Sestak AL, Shaver TS, Moser KL, Neas BR, Harley JB. Familial aggregation of lupus and autoimmunity in an unusual multiplex pedigree. J Rheumatol (1999) 26(7):1495-9.
44. Sabio JM, Milla E, Jimenez-Alonso J. A multicase family with primary Sjogren's syndrome. J Rheumatol (2001) 28(8):1932-4.
45. Houghton KM, Cabral DA, Petty RE, Tucker LB. Primary Sjogren's syndrome in dizygotic adolescent twins: one case with lymphocytic interstitial pneumonia. J Rheumatol (2005) 32(8):1603-6.
46. Ice JA, Li H, Adrianto I, Lin PC, Kelly JA, Montgomery CG, et al. Genetics of Sjogren's syndrome in the genome-wide association era. J Autoimmun (2012) 39(1-2):57-63. doi:10.1016/j.jaut.2012.01.008.
47. Korman BD, Alba MI, Le JM, Alevizos I, Smith JA, Nikolov NP, et al. Variant form of STAT4 is associated with primary Sjogren's syndrome. Genes Immun (2008) 9(3):267-70. doi:10.1038/gene.2008.1.
48. Nordmark G, Kristjansdottir G, Theander E, Eriksson P, Brun JG, Wang C, et al. Additive effects of the major risk alleles of IRF5 and STAT4 in primary Sjogren's syndrome. Genes Immun (2009) 10(1):68-76. doi:10.1038/gene.2008.94.
49. Nordmark G, Kristjansdottir G, Theander E, Appel S, Eriksson P, Vasaitis L, et al. Association of EBF1, FAM167A(C8orf13)-BLK and TNFSF4 gene variants with primary Sjogren's syndrome. Genes Immun (2011) 12(2):100-9. doi:10.1038/gene.2010.44.
50. Takaoka A, Yanai H, Kondo S, Duncan G, Negishi H, Mizutani T, et al. Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature (2005) 434(7030):243-9. doi:10.1038/nature03308.
51. Sigurdsson S, Nordmark G, Goring HH, Lindroos K, Wiman AC, Sturfelt G, et al. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am J Hum Genet (2005) 76(3):528-37. doi:10.1086/428480.
52. Dideberg V, Kristjansdottir G, Milani L, Libioulle C, Sigurdsson S, Louis E, et al. An insertion-deletion polymorphism in the interferon regulatory Factor 5 (IRF5) gene confers risk of inflammatory bowel diseases. Hum Mol Genet (2007) 16(24):3008-16. doi:10.1093/hmg/ddm259.
53. Sigurdsson S, Padyukov L, Kurreeman FA, Liljedahl U, Wiman AC, Alfredsson L, et al. Association of a haplotype in the promoter region of the interferon regulatory factor 5 gene with rheumatoid arthritis. Arthritis Rheum (2007) 56(7):2202-10. doi:10.1002/art.22704.
54. Dieude P, Guedj M, WipffJ, Avouac J, Fajardy I, Diot E, et al. Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmonary fibrosis. Arthritis Rheum (2009) 60(1):225-33. doi:10.1002/art.24183.
55. Liu X, Invernizzi P, Lu Y, Kosoy R, Bianchi I, Podda M, et al. Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet (2010) 42(8):658-60. doi:10.1038/ng.627.
56. Watford WT, Hissong BD, Bream JH, Kanno Y, Muul L, O'Shea JJ. Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunol Rev (2004) 202:139-56. doi:10.1111/j.0105-2896.2004.00211.x.
57. Kaplan MH. STAT4: a critical regulator of inflammation in vivo. Immunol Res (2005) 31(3):231-42. doi:10.1385/IR:31:3:231.
58. Remmers EF, Plenge RM, Lee AT, Graham RR, Hom G, Behrens TW, et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med (2007) 357(10):977-86. doi:10.1056/NEJMoa073003.
59. Rueda B, Broen J, Simeon C, Hesselstrand R, Diaz B, Suarez H, et al. The STAT4 gene influences the genetic predisposition to systemic sclerosis phenotype. Hum Mol Genet (2009) 18(11):2071-7. doi:10.1093/hmg/ddp119.
60. Mells GF, Floyd JA, Morley KI, Cordell HJ, Franklin CS, Shin SY, et al. Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis. Nat Genet (2011) 43(4):329-32. doi:10.1038/ng.789.
61. Nocturne G, Mariette X. Advances in understanding the pathogenesis of primary Sjogren's syndrome. Nat Rev Rheumatol (2013) 9(9):544-56. doi:10.1038/nrrheum.2013.110.
62. Rowe D, Griffiths M, Stewart J, Novick D, Beverley PC, Isenberg DA. HLA class I and II, interferon, interleukin 2, and the interleukin 2 receptor expression on labial biopsy specimens from patients with Sjogren's syndrome. Ann Rheum Dis (1987) 46(8):580-6. doi:10.1136/ard.46.8.580.
63. Thrane PS, Halstensen TS, Haanaes HR, Brandtzaeg P. Increased epithelial expression of HLA-DQ and HLA-DP molecules in salivary glands from patients with Sjogren's syndrome compared with obstructive sialadenitis. Clin Exp Immunol (1993) 92(2):256-62. doi:10.1111/j.1365-2249.1993.tb03389.x.
64. Manoussakis MN, Dimitriou ID, Kapsogeorgou EK, Xanthou G, Paikos S, Polihronis M, et al. Expression of B7 costimulatory molecules by salivary gland epithelial cells in patients with Sjogren's syndrome. Arthritis Rheum (1999) 42(2):229-39. doi:10.1002/1529-0131(199902)42:2<229::AID-ANR4>3.0.CO;2-X.
65. Dimitriou ID, Kapsogeorgou EK, Moutsopoulos HM, Manoussakis MN. CD40 on salivary gland epithelial cells: high constitutive expression by cultured cells from Sjogren's syndrome patients indicating their intrinsic activation. Clin Exp Immunol (2002) 127(2):386-92. doi:10.1046/j.1365-2249.2002.01752.x.
66. Amft N, Bowman SJ. Chemokines and cell trafficking in Sjogren's syndrome. Scand J Immunol (2001) 54(1-2):62-9. doi:10.1046/j.1365-3083.2001.00970.x.
67. Barone F, Bombardieri M, Rosado MM, Morgan PR, Challacombe SJ, De Vita S, et al. CXCL13, CCL21, and CXCL12 expression in salivary glands of patients with Sjogren's syndrome and MALT lymphoma: association with reactive and malignant areas of lymphoid organization. J Immunol (2008) 180(7):5130-40.
68. Tsunawaki S, Nakamura S, Ohyama Y, Sasaki M, Ikebe-Hiroki A, Hiraki A, et al. Possible function of salivary gland epithelial cells as nonprofessional antigen-presenting cells in the development of Sjogren's syndrome. J Rheumatol (2002) 29(9):1884-96.
69. Ittah M, Miceli-Richard C, Gottenberg JE, Sellam J, Eid P, Lebon P, et al. Viruses induce high expression of BAFF by salivary gland epithelial cells through TLR-and type-I IFN-dependent and -independent pathways. Eur J Immunol (2008) 38(4):1058-64. doi:10.1002/eji.200738013.
70. Lavie F, Miceli-Richard C, Ittah M, Sellam J, Gottenberg JE, Mariette X. B-cell activating factor of the tumour necrosis factor family expression in blood monocytes and T cells from patients with primary Sjogren's syndrome. Scand J Immunol (2008) 67(2):185-92. doi:10.1111/j.1365-3083.2007.02049.x.
71. Lavie F, Miceli-Richard C, Quillard J, Roux S, Leclerc P, Mariette X. Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjogren's syndrome. J Pathol (2004) 202(4):496-502. doi:10.1002/path.1533.
72. Ittah M, Miceli-Richard C, Eric Gottenberg J, Lavie F, Lazure T, Ba N, et al. B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjogren's syndrome. Arthritis Res Ther (2006) 8(2):R51. doi:10.1186/ar1912.
73. Strandberg L, Ambrosi A, Espinosa A, Ottosson L, Eloranta ML, Zhou W, et al. Interferon-alpha induces up-regulation and nuclear translocation of the Ro52 autoantigen as detected by a panel of novel Ro52-specific monoclonal antibodies. J Clin Immunol (2008) 28(3):220-31. doi:10.1007/s10875-007-9157-0.
74. Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH, et al. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis (2003) 8(3):237-49. doi:10.1023/A:1023668705040.
75. Gannot G, Bermudez D, Lillibridge D, Fox PC. Fas and Fas-mediated effects on a human salivary cell line in vitro: a model for immune-mediated exocrine damage in Sjogren's syndrome. Cell Death Differ (1998) 5(9):743-50. doi:10.1038/sj.cdd.4400414.
76. Matsumura R, Umemiya K, Goto T, Nakazawa T, Ochiai K, Kagami M, et al. Interferon gamma and tumor necrosis factor alpha induce Fas expression and anti-Fas mediated apoptosis in a salivary ductal cell line. Clin Exp Rheumatol (2000) 18(3):311-8.
77. Polihronis M, Tapinos NI, Theocharis SE, Economou A, Kittas C, Moutsopoulos HM. Modes of epithelial cell death and repair in Sjogren's syndrome (SS). Clin Exp Immunol (1998) 114(3):485-90. doi:10.1046/j.1365-2249.1998.00705.x.
78. Ohlsson M, Jonsson R, Brokstad KA. Subcellular redistribution and surface exposure of the Ro52, Ro60 and La48 autoantigens during apoptosis in human ductal epithelial cells: a possible mechanism in the pathogenesis of Sjogren's syndrome. Scand J Immunol (2002) 56(5):456-69. doi:10.1046/j.1365-3083.2002.01072_79.x.
79. Unoki H, Moriyama A, Tabaru A, Masumoto A, Otsuki M. Development of Sjogren's syndrome during treatment with recombinant human interferon-alpha-2b for chronic hepatitis C. J Gastroenterol (1996) 31(5):723-7. doi:10.1007/BF02347624.
80. Cummins MJ, Papas A, Kammer GM, Fox PC. Treatment of primary Sjogren's syndrome with low-dose human interferon alfa administered by the oromucosal route: combined phase III results. Arthritis Rheum (2003) 49(4):585-93. doi:10.1002/art.11199.
81. Khurshudian AV. A pilot study to test the efficacy of oral administration of interferon-alpha lozenges to patients with Sjogren's syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2003) 95(1):38-44. doi:10.1067/moe.2003.30.
82. De Santi L, Costantini MC, Annunziata P. Long time interval between multiple sclerosis onset and occurrence of primary Sjogren's syndrome in a woman treated with interferon-beta. Acta Neurol Scand (2005) 112(3):194-6. doi:10.1111/j.1600-0404.2005.00455.x.
83. Yamada S, Mori K, Matsuo K, Inukai A, Kawagashira Y, Sobue G. Interferon alfa treatment for Sjogren's syndrome associated neuropathy. J Neurol Neurosurg Psychiatry (2005) 76(4):576-8. doi:10.1136/jnnp.2004.049502.